Drug Database
Back to search

Poland· PL-100465775

Elymbus

A bimatoprost product containing bimatoprostum, registered in Poland by Laboratoires THEA. The same ATC class is registered in 19 of our 19 countries.

ATC S01EE03

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedElymbusATCS01EE03REGISTER NO.PL-100465775PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about bimatoprostumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Bimatoprost is registered in 19 of 19 countries.

Countries holding a registration under ATC S01EE03 (bimatoprost), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 11 of them publish a price we can compare per daily dose
Search bimatoprost products by name

Bimatoprost · ATC S01EE03

19 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Bimatoprostum
Manufacturer
Laboratoires THEA
Country
Poland (PL)
ATC code
S01EE03
ATC class
Bimatoprost
Defined daily dose
0.1 ml, AT
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05909991525668
  • gtin
    05909991525651

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

89 interactions on record for bimatoprost.

Graded by severity as the source publishes them — 89 info. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check bimatoprost against other medicinesHow interaction checks work

Bimatoprost · interactions on record

89 records

  • 89 info

Most severe, free to view

    Mechanism and what to do, in the interaction check
    Interaction register. Grades as the source publishes them.

    Same medicine, other countries

    Bimatoprost in 16 other countries

    What each register calls a product with the same active substance — salts and hydrates count as the same.

    All bimatoprost products

    Authorised across Europe · EMA

    The same active substance is authorised in 28 EEA countries. Names it is sold under:

    • Austria · Bima-Vision Sine, Bimato-Vision
    • Belgium · Bimatoprost Eg, Bimatoprost Eg (Eurogenerics)
    • Bulgaria · Бимаган, Биматопрост Абр
    • Cyprus · Bimatoprost Pharmathen, Birmost
    • Czechia · Bimatoprost Farmaprojects, Bimatoprost Olikla
    • Germany · Amiriox, Bimato-Vision
    • Denmark · Bimatoprost "hexal", Bimatoprost "stada"
    • Estonia · Elymbus
    • Spain · Amiriox, Bamixol
    • Finland · Bimatoprost, Bimatoprost Sandoz
    • France · Amiriox, Bimatoprost
    • United Kingdom (Northern Ireland) · Amiriox, Bimatoprost Alissa Healthcare Research
    • Greece · Birmost, Dacrysan
    • Croatia · Elymbus
    • Ireland · Elymbus, Eyreida
    • Iceland · Bimatoprost, Elymbus
    • Italy · Amiriox, Bialviz
    • Liechtenstein · Lumigan
    • Lithuania · Bimican, Bimifree
    • Luxembourg · Bimatoprost Eg, Bimatoprost Eg (Eurogenerics) Nv
    • Latvia · Bimican, Bimifre
    • Netherlands · Bimagan, Bimato-Vision
    • Norway · Bimaprez, Bimatoprost Hexal
    • Portugal · Amiriox, Bimatoprost Stulln
    • Romania · Amiriox, Bimagan
    • Sweden · Bimaprez, Bimatoprost
    • Slovenia · Elymbus
    • Slovakia · Bimatoprost Olikla, Elymbus

    Source: European Medicines Agency, Article 57 product data.

    Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

    For developers

    The same record over the API, and the raw payload
    GET /v1/drugs/3d8c7438-9625-4a82-b5a4-805da3ed57a7
GET /v1/drugs/3d8c7438-9625-4a82-b5a4-805da3ed57a7?format=fhir

    Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

    {
  "form": "Żel do oczu",
  "source": "urpl",
  "strength": "0,1 mg/g",
  "packaging": "05909991525651 ¦ Rp ¦ 151941\n30 poj. jednodawkowych 0,3 g\n05909991525668 ¦ Rp ¦ 151942\n90 poj. jednodawkowych 0,3 g",
  "substance": "Bimatoprostum 0.1 mg/g",
  "common_name": "Bimatoprostum",
  "pl_product_id": "100465775",
  "pozwolenie_nr": "28107",
  "auth_procedure": "DCP",
  "authorisation_validity": "2028-11-10"
}
    API referenceMCP serverPlans

    See everything about bimatoprost.

    This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

    Try it freeOpen in the console